Pharmaceuticals - Eastern Asia

  • Eastern Asia
  • In 2024, the projected revenue in the Pharmaceuticals market in Eastern Asia is expected to reach US$182.00bn.
  • Among the various markets, Oncology Drugs is the largest, with a projected market volume of US$32.15bn in 2024.
  • Looking ahead, the revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 5.36%, leading to a market volume of US$236.30bn by 2029.
  • Comparing globally, United States is projected to generate the highest revenue, amounting to US$630.30bn in 2024.
  • With its strong focus on research and development, Japan remains a global leader in the pharmaceutical industry.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Eastern Asia has been experiencing a steady growth in recent years, driven by various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors.

Customer preferences:
Customers in Eastern Asia are increasingly seeking out pharmaceutical products that are safe, effective, and affordable. This has led to a rise in demand for generic drugs, which are cheaper than their branded counterparts. In addition, customers are also placing a greater emphasis on preventive healthcare, leading to an increase in the consumption of vitamins, dietary supplements, and other health products.

Trends in the market:
In China, the pharmaceutical market has been growing rapidly due to the aging population and increasing healthcare spending. The government's push towards universal healthcare coverage has also contributed to the growth of the market. In Japan, the market has been driven by the increasing demand for innovative drugs and the rise of biologics. South Korea's market has been growing due to the increasing prevalence of chronic diseases and the government's efforts to promote the development of the pharmaceutical industry.

Local special circumstances:
Each country in Eastern Asia has its own unique set of circumstances that affect the pharmaceutical market. For example, in China, the government plays a significant role in regulating the market and has been implementing policies to promote the development of domestic pharmaceutical companies. In Japan, the market is highly regulated and the approval process for new drugs can be lengthy and expensive. South Korea has been promoting the development of the pharmaceutical industry through various initiatives such as tax incentives and funding for research and development.

Underlying macroeconomic factors:
The pharmaceutical market in Eastern Asia is also influenced by underlying macroeconomic factors such as GDP growth, inflation rates, and exchange rates. The region has been experiencing steady economic growth, which has led to an increase in healthcare spending. In addition, the depreciation of certain currencies such as the Japanese yen and the Korean won has made pharmaceutical exports more competitive, leading to an increase in exports from these countries.Overall, the Pharmaceuticals market in Eastern Asia is expected to continue growing in the coming years, driven by factors such as customer preferences, local special circumstances, and underlying macroeconomic factors. However, the market is also facing challenges such as increasing competition and regulatory hurdles, which could impact its growth in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)